CRIS · Curis Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.44M | $10.91M | $10.02M | $10.16M | $10.65M | $10.84M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $28.25M | $38.56M | $39.50M | $43.28M | $34.88M | $23.07M |
| SG&A | $14.05M | $16.79M | $18.65M | $19.65M | $17.30M | $12.13M |
| Total Operating Expenses | $42.34M | $55.45M | $58.35M | $63.18M | $52.71M | $35.73M |
| D&A | $169.0K | $203.0K | $255.0K | $233.0K | $158.0K | $144.0K |
| Operating Income | ($5.71M) | ($44.54M) | ($48.33M) | ($53.02M) | ($42.06M) | ($24.90M) |
| Interest Expense | - | - | - | - | $0 | $0 |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($7.58M) | ($43.39M) | ($47.41M) | ($56.67M) | ($45.44M) | ($29.91M) |
| EPS - Basic | ($0.58) | ($6.88) | ($8.96) | $0.61 | ($0.61) | - |
| EPS - Diluted | ($0.58) | ($6.88) | ($8.96) | $0.61 | ($0.61) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.06M | $20.00M | $26.68M | $19.66M | $40.01M | $129.61M |
| Accounts Receivable | $0 | $3.35M | $2.79M | $2.98M | $3.22M | $3.04M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $5.61M | $3.02M | $3.17M | $3.19M | $6.42M | $4.17M |
| Current Assets | $6.92M | $26.39M | $60.91M | $92.12M | $122.38M | $172.75M |
| Total Assets | $19.97M | $41.27M | $77.28M | $108.85M | $162.30M | $204.36M |
| Current Liabilities | $14.08M | $19.03M | $13.52M | $10.01M | $13.44M | $10.08M |
| Long-term Debt | - | - | - | - | - | $0 |
| Total Liabilities | $14.50M | $47.26M | $57.61M | $62.30M | $71.59M | $73.69M |
| Stockholders' Equity | $5.46M | ($6.00M) | $19.67M | $46.55M | $90.71M | $130.67M |
| Retained Earnings | ($1.25B) | ($1.24B) | ($1.20B) | ($1.15B) | ($1.09B) | ($1.05B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($27.20M) | ($39.56M) | ($38.43M) | ($54.34M) | ($37.62M) | ($25.74M) |
| Investing Cash Flow | $2.50M | $29.44M | $37.79M | $33.02M | ($47.90M) | ($49.05M) |
| Financing Cash Flow | $9.77M | $3.44M | $7.58M | $867.0K | ($4.17M) | $188.81M |
| CapEx | - | - | $0 | $416.0K | $0 | $677.0K |
| Free Cash Flow | - | - | ($38.43M) | ($54.75M) | ($37.62M) | ($26.42M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -60.5% | -408.3% | -482.2% | -521.7% | -395.0% | -229.8% |
| EBITDA margin | -58.7% | -406.5% | -479.7% | -519.5% | -393.5% | -228.5% |
| Net margin | -80.3% | -397.8% | -473.0% | -557.7% | -426.7% | -276.0% |
| Free cash flow margin | - | - | -383.5% | -538.8% | -353.3% | -243.8% |
| FCF / Net income | - | - | 0.81 | 0.97 | 0.83 | 0.88 |
| R&D / Revenue | 299.2% | 353.5% | 394.1% | 425.9% | 327.6% | 212.9% |
| SG&A / Revenue | 148.7% | 153.9% | 186.0% | 193.3% | 162.4% | 112.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -38.0% | -105.1% | -61.4% | -52.1% | -28.0% | -14.6% |
| Return on equity | -138.8% | 723.4% | -241.0% | -121.7% | -50.1% | -22.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.49 | 1.39 | 4.51 | 9.20 | 9.11 | 17.14 |
| Quick ratio | 0.49 | 1.39 | 4.51 | 9.20 | 9.11 | 17.14 |
| Cash ratio | 0.36 | 1.05 | 1.97 | 1.96 | 2.98 | 12.86 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 3.66 | -6.88 | 3.93 | 2.34 | 1.79 | 1.56 |
| Liabilities / Assets | 0.73 | 1.15 | 0.75 | 0.57 | 0.44 | 0.36 |
| Efficiency | ||||||
| Asset turnover | 0.47 | 0.26 | 0.13 | 0.09 | 0.07 | 0.05 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 0d | 112d | 102d | 107d | 111d | 103d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | 18.0x | - | - |
| P / B | 2.4x | - | 3.4x | 22.1x | 51.1x | - |
| P / S | 1.4x | 1.8x | 6.7x | 101.1x | 435.1x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -13.4% | 8.8% | -1.4% | -4.6% | -1.7% | 8.3% |
| Revenue CAGR (3y) | -2.4% | 0.8% | -2.6% | 0.5% | 2.5% | 3.1% |
| Revenue CAGR (5y) | -2.7% | 1.7% | 0.3% | 0.5% | 7.2% | 6.6% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 87.2% | 7.8% | 8.8% | -26.0% | -68.9% | -2.2% |
| Net income growth (YoY) | 82.5% | 8.5% | 16.3% | -24.7% | -51.9% | 6.9% |
| EPS growth (YoY) | 91.6% | 23.2% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 29.8% | -45.5% | -42.4% | -0.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -57.7% | -48.7% | -30.6% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$9.44M totalReportable Segment$9.44M · 100.0%
Product / service
$9.40M totalGross Royalty Revenue$9.40M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-53.43
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing CURIS INC against the 5 most active filers in the same SIC group.